← FDA DRUG APPROVALS

FDA NDA · NDA020089

ZOVIRAX

Sponsor: PHARMOBEDIENT

APPLICATION
NDA020089
TYPE
NDA
ORIGINAL APPROVAL
1991-04-30
LATEST ACTION
2025-11-12
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

ZOVIRAX · ReferenceDiscontinued
ACYCLOVIR 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
ZOVIRAX · ReferenceDiscontinued
ACYCLOVIR 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL

Approval history

2025-11-12Labeling · Supplement 21 · standardLabelAP
2008-08-08Labeling · Supplement 20 · standardLetterAP
2005-12-09Labeling · Supplement 19 · standardLetterAP
2004-05-19Labeling · Supplement 18 · standardLabelAP
2001-11-14Labeling · Supplement 15 · standardLabelAP
2001-11-14Labeling · Supplement 16 · standardLabelAP
2000-07-12Manufacturing (CMC) · Supplement 14 · standardAP
2000-03-15Labeling · Supplement 12 · standardAP
1999-06-10Manufacturing (CMC) · Supplement 13 · standardAP
1997-05-29Labeling · Supplement 11 · standardAP
1997-01-08Labeling · Supplement 10 · standardAP
1996-10-29Manufacturing (CMC) · Supplement 9 · standardAP
1995-09-07Manufacturing (CMC) · Supplement 5 · standardAP
1995-05-31Manufacturing (CMC) · Supplement 8 · standardAP
1995-04-12Labeling · Supplement 7 · standardAP
1994-04-14Labeling · Supplement 4 · standardAP
1993-11-09Manufacturing (CMC) · Supplement 3 · standardAP
1993-04-22Labeling · Supplement 1AP
1992-02-26Efficacy · Supplement 2ReviewAP
1991-04-30Type 3 - New Dosage Form · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →